COLLEGIUM PHARMACEUTICAL INC (COLL)
US19459J1043 - Common Stock
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Commit To Purchase Collegium Pharmaceutical At $17.50, Earn 6.7% Annualized Using Options
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty...
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
Collegium Pharmaceutical Non-GAAP EPS of $1.58 beats by $0.33, revenue of $149.7M beats by $2.16M (NASDAQ:COLL)
Collegium Pharmaceutical beats expectations with record Q4 earnings and revenue.
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of...
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium Provides 2024 Financial Guidance
Commit To Purchase Collegium Pharmaceutical At $22.50, Earn 5.3% Using Options
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium Pharmaceutical announces $25M accelerated share repurchase deal (NASDAQ:COLL)
Collegium Pharmaceutical announces a $25M accelerated share repurchase deal with Jefferies as part of its authorized $100M share repurchase program.
Collegium Announces $25 Million Accelerated Share Repurchase Program
Collegium to Participate in Upcoming Investor Conferences
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium Reports Third Quarter 2023 Financial Results
Collegium Reports Third Quarter 2023 Financial Results
– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – –...
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Commit To Purchase Collegium Pharmaceutical At $15, Earn 4.3% Using Options
Bullish Two Hundred Day Moving Average Cross - COLL
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium pain med Nucynta gets US market exclusivity extension (COLL)
Collegium Pharmaceutical (COLL) said the US market exclusivity period for its pain medication Nucynta has been extended to July 3, 2026, from June 27, 2025. Read more here.
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical...
Collegium announces $50M accelerated share repurchase program (NASDAQ:COLL)
Collegium Pharmaceutical (COLL) on Monday said it had entered into an Accelerated Share Repurchase agreement with Jefferies to repurchase $50M of the company’s common stock.Collegium...